As the market for GLP-1 weight loss drugs continues to grow, consumers fed up with needles now have two options in pill form. Eli Lilly, the maker of Zepbound, received FDA approval for its drug orforgaliprone, to be sold under the brand name Foundayo, on April 1, 2026, following Novo Nordisk, which received approval for the Vegovy pill in December 2025. Unlike injectable forms of drugs…